Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2021

View Archived Issues

China's NMPA clears initiation of clinical trials with ESG-401 for solid tumors

RNA-directed gene therapy targeting shPromA/shCCR5 tested in chronic HIV infection model

Dosing starts in phase Ib study of Zotatifin in COVID-19

Annexon expands its clinical programs for ANX-009 and ANX-005 in autoimmune disease

FDA accepts IND application for ATRS-1902 for adrenal crisis rescue

ECO-RESET study of SER-287 in UC does not meet primary endpoint

Chinese researchers patent coagulation factor XIa inhibitors

Wuhan LL Science and Technology Development divulges P2X4 receptor antagonists

Memorial Sloan Kettering Cancer Center presents new ULK1 inhibitors

Blue Oak Pharmaceuticals describes new antidepressants

Function follows form: Predicted protein structures for human proteome now freely accessible

South Korea's MDFS clears initiation of phase I study of lenzilumab for COVID-19

Pacylex recruits patients with solid malignancies and B-cell lymphoma in phase I trial of PCLX-001

A new variant in GATA1 gene tied to bleeding diathesis and platelet dysfunction

CFT-2718 shows promising tumor growth reduction in models of SCLC

Gilead studies GS-5718 in phase Ib for cutaneous lupus erythematosus

TAE Life Sciences nominates product candidates for use with BNCT

Targeting IL-3 signaling reduces AD-related pathology

A novel variant in the TPM4 gene causes macrothrombocytopenia

Adverum will not pursue development of ADVM-022 for DME

Alzamend reports toxicology results for AL-002 in transgenic mouse model of Alzheimer's disease

ExCellThera initiates phase I study of ECT-001-CB in sickle cell disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...